No biomarker
|
Medulloblastoma
|
No biomarker
|
Medulloblastoma
|
carmustine Sensitive: A1 - Approval
FDA - 1 week (NewA1)
|
carmustine Sensitive: A1 - Approval
FDA - 1 week - (New A1)
|
No biomarker
|
Medulloblastoma
|
No biomarker
|
Medulloblastoma
|
cisplatin + cyclophosphamide + vincristine Sensitive: A2 - Guideline
|
cisplatin + cyclophosphamide + vincristine Sensitive: A2 - Guideline
|
No biomarker
|
Medulloblastoma
|
No biomarker
|
Medulloblastoma
|
cisplatin + vincristine + lomustine Sensitive: A2 - Guideline
|
cisplatin + vincristine + lomustine Sensitive: A2 - Guideline
|
No biomarker
|
Medulloblastoma
|
No biomarker
|
Medulloblastoma
|
cyclophosphamide Sensitive: A2 - Guideline
|
cyclophosphamide Sensitive: A2 - Guideline
|
No biomarker
|
Medulloblastoma
|
No biomarker
|
Medulloblastoma
|
vismodegib Sensitive: A2 - Guideline
|
vismodegib Sensitive: A2 - Guideline
|
No biomarker
|
Medulloblastoma
|
No biomarker
|
Medulloblastoma
|
cisplatin + etoposide IV Sensitive: A2 - Guideline
|
cisplatin + etoposide IV Sensitive: A2 - Guideline
|
No biomarker
|
Medulloblastoma
|
No biomarker
|
Medulloblastoma
|
etoposide oral Sensitive: A2 - Guideline
|
etoposide oral Sensitive: A2 - Guideline
|
No biomarker
|
Medulloblastoma
|
No biomarker
|
Medulloblastoma
|
temozolomide Sensitive: A2 - Guideline
|
temozolomide Sensitive: A2 - Guideline
|
No biomarker
|
Medulloblastoma
|
No biomarker
|
Medulloblastoma
|
cyclophosphamide + etoposide oral Sensitive: A2 - Guideline
|
cyclophosphamide + etoposide oral Sensitive: A2 - Guideline
|
No biomarker
|
Medulloblastoma
|
No biomarker
|
Medulloblastoma
|
carboplatin + cyclophosphamide + etoposide oral Sensitive: A2 - Guideline
|
carboplatin + cyclophosphamide + etoposide oral Sensitive: A2 - Guideline
|
No biomarker
|
Medulloblastoma
|
No biomarker
|
Medulloblastoma
|
CX-4945 Sensitive: B - Late Trials
|
CX-4945 Sensitive: B - Late Trials
|
PTCH1 mutation
|
Medulloblastoma
|
PTCH1 mutation
|
Medulloblastoma
|
vismodegib Sensitive: C3 – Early Trials
|
vismodegib Sensitive: C3 – Early Trials
|
PTCH1 deletion
|
Medulloblastoma
|
PTCH1 deletion
|
Medulloblastoma
|
IPI 926 oral Sensitive: D – Preclinical
|
IPI 926 oral Sensitive: D – Preclinical
|
SUFU deletion
|
Medulloblastoma
|
SUFU deletion
|
Medulloblastoma
|
sonidegib Resistant: D – Preclinical
|
sonidegib Resistant: D – Preclinical
|
MYC expression
|
Medulloblastoma
|
MYC expression
|
Medulloblastoma
|
JHU395 Sensitive: D – Preclinical
|
JHU395 Sensitive: D – Preclinical
|
SMO D477G
|
Medulloblastoma
|
SMO D477G
|
Medulloblastoma
|
itraconazole Sensitive: D – Preclinical
|
itraconazole Sensitive: D – Preclinical
|
MYCN amplification
|
Medulloblastoma
|
MYCN amplification
|
Medulloblastoma
|
sonidegib Resistant: D – Preclinical
|
sonidegib Resistant: D – Preclinical
|
PTCH1 mutation
|
Medulloblastoma
|
PTCH1 mutation
|
Medulloblastoma
|
sonidegib Sensitive: D – Preclinical
|
sonidegib Sensitive: D – Preclinical
|
SUFU mutation
|
Medulloblastoma
|
SUFU mutation
|
Medulloblastoma
|
SMO protein inhibitor Resistant: D – Preclinical
|
SMO protein inhibitor Resistant: D – Preclinical
|
PTCH1 mutation
|
Medulloblastoma
|
PTCH1 mutation
|
Medulloblastoma
|
SMO protein inhibitor Sensitive: D – Preclinical
|
SMO protein inhibitor Sensitive: D – Preclinical
|
SMO D473H
|
Medulloblastoma
|
SMO D473H
|
Medulloblastoma
|
vismodegib Resistant: D – Preclinical
|
vismodegib Resistant: D – Preclinical
|
SMO D473H
|
Medulloblastoma
|
SMO D473H
|
Medulloblastoma
|
IPI 926 oral Sensitive: D – Preclinical
|
IPI 926 oral Sensitive: D – Preclinical
|
TP53 mutation
|
Medulloblastoma
|
TP53 mutation
|
Medulloblastoma
|
CUDC-907 Sensitive: D – Preclinical
|
CUDC-907 Sensitive: D – Preclinical
|
TP53 mutation
|
Medulloblastoma
|
TP53 mutation
|
Medulloblastoma
|
AN2025 + panobinostat Sensitive: D – Preclinical
|
AN2025 + panobinostat Sensitive: D – Preclinical
|
TP53 mutation
|
Medulloblastoma
|
TP53 mutation
|
Medulloblastoma
|
panobinostat Sensitive: D – Preclinical
|
panobinostat Sensitive: D – Preclinical
|
TP53 mutation
|
Medulloblastoma
|
TP53 mutation
|
Medulloblastoma
|
AN2025 Resistant: D – Preclinical
|
AN2025 Resistant: D – Preclinical
|
TP53 mutation
|
Medulloblastoma
|
TP53 mutation
|
Medulloblastoma
|
AN2025 + sirolimus Sensitive: D – Preclinical
|
AN2025 + sirolimus Sensitive: D – Preclinical
|
MYC amplification
|
Medulloblastoma
|
MYC amplification
|
Medulloblastoma
|
PCM-075 Sensitive: D – Preclinical
|
PCM-075 Sensitive: D – Preclinical
|
MYCN amplification
|
Medulloblastoma
|
MYCN amplification
|
Medulloblastoma
|
olaparib + MK-8776 Sensitive: D – Preclinical
|
olaparib + MK-8776 Sensitive: D – Preclinical
|